Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques

Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques

The periodic emergence of SARS-CoV-2 variants of concern (VOCs) with unpredictable clinical severity and ability to escape preexisting immunity emphasizes the continued need for antiviral interventions. Two small molecule inhibitors, molnupiravir (MK-4482), a nucleoside analog, and nirmatrelvir (PF-...

Full description

Bibliographic Details
Main Authors:	Kyle Rosenke, Matt C. Lewis, Friederike Feldmann, Eric Bohrnsen, Benjamin Schwarz, Atsushi Okumura, W. Forrest Bohler, Julie Callison, Carl Shaia, Catharine M. Bosio, Jamie Lovaglio, Greg Saturday, Michael A. Jarvis, Heinz Feldmann
Format:	Article
Language:	English
Published:	American Society for Clinical investigation 2023-02-01
Series:	JCI Insight
Subjects:	COVID-19
Online Access:	https://doi.org/10.1172/jci.insight.166485

Similar Items

Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
by: Kyle Rosenke, et al.
Published: (2022-07-01)

Use of Favipiravir to Treat Lassa Virus Infection in Macaques
by: Kyle Rosenke, et al.
Published: (2018-09-01)

Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models
by: Kyle Rosenke, et al.
Published: (2020-12-01)

A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever
by: David W. Hawman, et al.
Published: (2024-05-01)

Histopathologic Characterization of Experimental Peracute SARS-CoV-2 Infection in the Syrian Hamster
by: Chad S. Clancy, et al.
Published: (2023-08-01)

Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
by: Kyle Rosenke, et al.
Published: (2021-04-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

UK B.1.1.7 (Alpha) variant exhibits increased respiratory replication and shedding in nonhuman primates
by: Kyle Rosenke, et al.
Published: (2021-01-01)

Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge
by: Andrea Marzi, et al.
Published: (2019-11-01)

Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques
by: Kim J. Hasenkrug, et al.
Published: (2021-08-01)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
by: Maria Mazzitelli, et al.
Published: (2023-01-01)

A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
by: David Safronetz, et al.
Published: (2015-04-01)

Domestic Pig Unlikely Reservoir for MERS-CoV
by: Emmie de Wit, et al.
Published: (2017-06-01)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
by: Victoria Kauer, et al.
Published: (2023-05-01)

Intradermal delivery of a synthetic DNA vaccine protects macaques from Middle East respiratory syndrome coronavirus
by: Ami Patel, et al.
Published: (2021-05-01)

Route of Francisella tularensis infection informs spatiotemporal metabolic reprogramming and inflammation in mice.
by: Forrest Jessop, et al.
Published: (2023-01-01)

Route of Francisella tularensis infection informs spatiotemporal metabolic reprogramming and inflammation in mice
by: Forrest Jessop, et al.
Published: (2023-01-01)

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
by: Ahmed O. Hassan, et al.
Published: (2021-04-01)

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
by: Guozhang Lin, et al.
Published: (2025-02-01)

Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
by: Robert M. Cox, et al.
Published: (2023-08-01)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
by: Ivan Gentile, et al.
Published: (2022-10-01)

An atlas of gross and histologic lesions and immunohistochemical immunoreactivity during the temporal progression of aerosolized Lassa virus induced hemorrhagic fever in cynomolgus macaques
by: Forrest Bohler, et al.
Published: (2024-02-01)

Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain
by: Andrea Marzi, et al.
Published: (2015-10-01)

Ebola Virus IgG Seroprevalence in Southern Mali
by: Sidy Bane, et al.
Published: (2021-06-01)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study
by: Abraham Ka-chung Wai, et al.
Published: (2023-05-01)

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan
by: Akira Yuasa, et al.
Published: (2025-02-01)

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
by: Mei-Ping Chen, et al.
Published: (2024-02-01)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
by: Ioannis Karniadakis, et al.
Published: (2023-10-01)

Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate modelResearch in context
by: Emmie de Wit, et al.
Published: (2023-01-01)

The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
by: Anna Gidari, et al.
Published: (2022-07-01)

Lassa Virus Treatment Options
by: Frederick Hansen, et al.
Published: (2021-04-01)

Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection
by: Kyle Rosenke, et al.
Published: (2020-01-01)

Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques.
by: Barry Rockx, et al.
Published: (2011-04-01)

Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques
by: Joseph Prescott, et al.
Published: (2018-02-01)

Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation
by: Kwok WC, et al.
Published: (2024-01-01)

Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
by: Yoshikazu Mutoh, et al.
Published: (2023-03-01)

Comparative Evaluation of GS-441524, Teriflunomide, Ruxolitinib, Molnupiravir, Ritonavir, and Nirmatrelvir for In Vitro Antiviral Activity against Feline Infectious Peritonitis Virus
by: Subarna Barua, et al.
Published: (2023-08-01)

<i>Mastomys natalensis</i> Has a Cellular Immune Response Profile Distinct from Laboratory Mice
by: Tsing-Lee Tang-Huau, et al.
Published: (2021-04-01)

The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever
by: Viviane M. Andrade, et al.
Published: (2024-11-01)

Multidrug Combinations against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir and/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia
by: Denise Siegrist, et al.
Published: (2024-09-01)